Kura Oncology Quarterly Cash Flow Statement
NASDAQ: KURAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
10.60+0.08 (+0.76%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kura Oncology free cash flow
In the quarter ended Jun 30, 2026, Kura Oncology generated -$62.5 million of operating cash flow and spent $656,000 on capital expenditures. That left free cash flow of -$63.2 million, a free-cash-flow margin of -302.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Kura Oncology cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -68.33M | -73.33M | -81.00M | -74.12M | -66.12M | -57.43M | -19.22M | -54.40M | -50.84M | -49.52M | -42.79M | -38.60M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 369.00K | 355.00K | 403.00K | 164.00K | 224.00K | 241.00K | 204.00K | 208.00K | 202.00K | 234.00K | 214.00K | 216.00K |
| Stock-Based Compensation | 8.21M | 8.42M | 11.35M | 10.96M | 6.95M | 7.84M | 8.63M | 8.32M | 8.43M | 8.51M | 7.17M | 7.09M |
| Change in Working Capital | -12.41M | -8.95M | 159.18M | -13.27M | 22.92M | -9.99M | 5.22M | 6.03M | 2.41M | -5.32M | 5.11M | 4.73M |
| Operating Cash Flow | -62.55M | -85.85M | 117.27M | -80.63M | -28.78M | -71.93M | 269.13M | -43.44M | -42.53M | -48.84M | -34.31M | -29.03M |
| Capital Expenditures | -656.00K | -128.00K | -2.32M | -2.57M | -1.46M | -292.00K | -372.00K | 0 | -16.00K | -84.00K | -16.00K | -20.00K |
| Investing Cash Flow | 92.21M | -24.23M | -64.60M | 93.97M | 58.94M | -101.41M | -94.95M | 45.53M | 43.17M | -95.34M | 42.20M | 8.56M |
| Financing Cash Flow | 1.50M | 69.00K | 1.14M | 0 | 515.00K | 143.00K | 806.00K | 2.20M | 3.04M | 148.37M | 691.00K | 84.00K |
| Net Change in Cash | 31.16M | -110.02M | 53.81M | 13.34M | 30.68M | -173.19M | 174.98M | 4.30M | 3.68M | 4.19M | 8.58M | -20.38M |
| Free Cash Flow | -63.20M | -85.98M | 114.95M | -83.19M | -30.23M | -72.22M | 268.76M | -43.44M | -42.55M | -48.93M | -34.32M | -29.05M |
This table shows 12 quarterly periods of Kura Oncology's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow KURA's reporting calendar. What is a cash flow statement?